Blueprint
GT BIOPHARMA, INC.
310 N. Westlake
Blvd., Suite 206
Westlake Village, CA 91362
March 5, 2019
VIA EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
|
Re:
|
GT Biopharma, Inc.
|
|
|
Registration Statement on Form S-3 (File No.
333-229667)
|
|
|
Request for Acceleration of Effective Date
|
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933,
as amended, GT Biopharma, Inc. hereby requests that the Securities
and Exchange Commission accelerate the effective date of the
above-referenced Registration Statement on Form S-3 (File No.
333-229667) and declare the Registration Statement effective as of
Friday, March 8, 2019, at 4:00 p.m., Eastern time, or as soon as
practicable thereafter.
Please contact the undersigned at (310) 977-7394, or Gary R.
Henrie, Attorney at Law at (309) 313-5092, with any questions.
Also, please notify Mr. Henrie when this request for acceleration
has been granted.
|
Very
truly yours,
GT
Biopharma, Inc.
|
|
|
|
|
|
|
By:
|
/s/ Raymond Urbanski
|
|
|
|
Name:
Raymond Urbanski
Title:
Chief Executive Officer
|
|
|
|
|
|
cc:
Gary R. Henrie, Attorney at Law
|
|
|
|